You are here

Home » Content

Guillain Barre Sendromu Tanısıyla Yatarak Rehabilitasyon Uygulanan Olgularımızın Klinik ve Fonksiyonel İzlem Sonuçları

Clinical and Functional Outcome of Patients With Guillian Barre Syndrome Following Inpatient Rehabilitation

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Guillain Barre Syndrome (GBS) is an acute demyelinating inflammatory polyradiculoneuropathy which may lead to significant complications, disability and psychosocial problems. This study was designed to evaluate clinical features, complications and functional outcome of patients with GBS following inpatient rehabilitation. Clinical features and functional outcome measures assessed by functional independence measure, functional ambulation score and Hughes score of 18 patients with GBS who have undergone inpatient rehabilitation were evaluated in this retrospective study. Mean duration until admission to rehabilitation clinic was 57.5 + 20.5 (12-382) days and mean length of stay was 33.5 + 4.9 (4-77) days and neuropathic pain was noted in half of the patients. Significant improvements were noted in all functional outcome measures following inpatient rehabilitation. Length of stay was significantly longer in patients with higher (worse) baseline Hughes score. Our findings suggest that there is ongoing need for rehabilitation and significant improvements can be obtained by inpatient rehabilitation in GBS patients with residual ambulation problems.
Bookmark/Search this post with
Abstract (Original Language): 
Akut demyelinizan inflamatuvar bir poliradikülonöropati olarak tanımlanan Guillain Barre Sendromu (GBS), yol açtığı komplikasyonlar, yetiyitimi ve bunlarla ilişkili psikososyal sorunlar nedeniyle rehabilitasyon açısından önemli bir klinik tablodur. Bu çalışmanın amacı yatarak rehabilite edilen GBS olgularını klinik özellikler, komplikasyonlar ve fonksiyonel durum açısından incelemektir. Bu retrospektif çalışmada GBS tanısı ile rehabilitasyon amacıyla yatarak tedavi edilen 18 olgunun dosya bilgilerinden klinik özellikleri ve fonksiyonel bağımsızlık ölçümü skoru, fonksiyonel ambulasyon skoru ve Hughes skoru ile yapılan fonksiyonel değerlendirme sonuçları incelenmiştir. Rehabilitasyon kliniğine yatışa kadar geçen süre ortalaması 57,5 + 20,5 (12-382) gün ve klinikte yatış süresi ortalaması 33,5 + 4,9 (4-77) gün olan olguların yarısında nöropatik ağrı saptanmıştır. Fonksiyonel bağımsızlık ölçümü skoru, fonksiyonel ambulasyon skoru ve Hughes skoru ile yapılan değerlendirmelerde rehabilitasyon sonrasında anlamlı düzelmeler saptanmıştır. Hughes skoru yüksek (daha kötü) olan olgularda yatış süresi daha uzun olmuştur. Bulgularımız ambulasyon sorunu olan GBS’de rehabilitasyon gereksiniminin sürdüğünü ve rehabilitasyon sonucunda fonksiyonel iyileşmeler sağlanabildiğini desteklemektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-guillain-barre-sendromu-tanisiyla-yatarak-rehabilitasyon-uygulanan-olgularimizin-klinik-fonksiyonel-izlem-sonuclari.pdf
  • 2
83-87
  • Turkish

REFERENCES

References: 

1. Alter M. The epidemiology of Guillain-Barre syndrome. Ann
Neurol 1990;27 Suppl:S7-12
2. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet
2005;366:1653-66
3. Pithadia AB, Kakadia N. Guillain-Barre syndrome (GBS).
Pharmacol Rep 2010;62:220-32
4. Meythaler JM, DeVivo MJ, Braswell WC. Rehabilitation
outcomes of patients who have developed Guillain-Barre syndrome. Am J Phys Med Rehabil 1997;76:411-9
5. Winer JB, Hughes RA, Osmond C. A prospective study of
acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51:605-12
6. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in south east England. J Neurol Neurosurg Psychiatry 1998;64:74-7
7. Mullings KR, Alleva JT, Hudgins TH. Rehabilitation of Guillain-Barre syndrome. Dis Mon 2010;56:288-92
8. Hiraga A, Mori M, Ogawara K, Kojima S, Kanesaka T, Misawa
S, Hattori T, Kuwabara S. Recovery patterns and long term
prognosis for axonal Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2005;76:719-22
9. Khan F, Pallant JF, Ng L, Bhasker A. Factors associated with
long-term functional outcomes and psychological sequelae in
Guillain-Barre syndrome. J Neurol 2010;257:2024-31
10. Demir SO, Koseoglu F. Factors associated with health-related
quality of life in patients with severe Guillain-Barre syndrome.
Disabil Rehabil 2008;30:593-9
11. Kucukdeveci AA, Yavuzer G, Elhan AH, Sonel B, Tennant A.
Adaptation of the Functional Independence Measure for use in
Turkey. Clin Rehabil 2001;15:311-9
12. Holden MK, Gill KM, Magliozzi MR. Gait assessment for
neurologically impaired patients. Standards for outcome assessment. Phys Ther 1986;66:1530-9
13. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM.
Controlled trial prednisolone in acute polyneuropathy. Lancet
1978;312:750-3
14. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver
agreement in the assessment of muscle strength and functional
abilities in Guillain-Barre syndrome. Muscle Nerve
1991;14:1103-9
15. Kocer A. Guillain Barre: Klinik ve prognostik özellikler. Fırat
Tıp Dergisi 2004;9:108-11
16. Terzi M, Turker H, Onar M. Guillain Barre Sendromunda
klinik ve demografik özellikler. Fırat Tıp Dergisi 2007;12:112-
4
17. Newswanger DL, Warren CR. Guillain-Barre syndrome. Am
Fam Physician 2004;69:2405-10
18. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in
Guillain-Barre syndrome. Neurology 1997;48:328-31
19. Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs
BC, van Doorn PA. Pain in Guillain-Barre syndrome: a longterm follow-up study. Neurology 2010;75:1439-47
20. Tripathi M, Kaushik S. Carbamezapine for pain management in
Guillain-Barre syndrome patients in the intensive care unit. Crit
Care Med 2000;28:655-8
21. Pandey CK, Raza M, Tripathi M, Navkar DV, Kumar A, Singh
UK. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre syndrome
patients in the intensive care unit. Anesth Analg 2005;101:220-
5

Thank you for copying data from http://www.arastirmax.com